Sangamo’s turn to gene therapy scores early win in Fabry

Gene replacement therapy is proving to be a promising platform for Sangamo, which has also explored a range of gene editing and gene regulation technologies during its more than 25 years of operations.

Sangamo Biosciences Inc. (NASDAQ:SGMO) was founded in 1995 to develop zinc finger transcription factor-based research tools and therapies to control gene expression before shifting its focus to gene editing with zinc finger nucleases. ZFNs were a pioneering gene editing technology, but most development in the field has since shifted to CRISPR, which offers a simplified construction...